Keros Therapeutics (NASDAQ:KROS) Lowered to Market Perform Rating by William Blair

William Blair lowered shares of Keros Therapeutics (NASDAQ:KROS) from an outperform rating to a market perform rating in a research note issued to investors on Thursday, MarketBeat reports.

Several other research firms have also recently commented on KROS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.22.

Keros Therapeutics Trading Down 73.2 %

KROS stock opened at $18.43 on Thursday. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00. The company’s 50 day simple moving average is $59.95 and its 200-day simple moving average is $52.83.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same period last year, the business posted ($1.33) earnings per share. The firm’s revenue was up 4750.0% on a year-over-year basis. As a group, analysts predict that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several large investors have recently added to or reduced their stakes in KROS. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. acquired a new position in shares of Keros Therapeutics during the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Keros Therapeutics in the second quarter valued at $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the 3rd quarter valued at $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.